Back to Authors

Mangaonkar, Abhishek A.

https://orcid.org/0000-0003-2458-9887

A5012298768 | I1330342723

Mayo Clinic

Citations 247

IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4863-4864

10.1182/blood-2022-168053

Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3233-3234

10.1182/blood-2022-167967

Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3235-3236

10.1182/blood-2022-169319

Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9675-9676

10.1182/blood-2022-163485

Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12353-12354

10.1182/blood-2022-155561

TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9798-9799

10.1182/blood-2022-165859

Clonal Hematopoiesis in Vexas Syndrome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 5745-5746

10.1182/blood-2022-160263

Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1286-1287

10.1182/blood-2022-165491

Response Rates to Venetoclax Based Therapies in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12238-12240

10.1182/blood-2022-165470

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias of Undetermined Significance

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2893-2894

10.1182/blood-2022-165163